Department of Neurology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Aug 15;24(8):948-953. doi: 10.7499/j.issn.1008-8830.2204021.
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a central nervous system disease characterized by neurological and psychiatric symptoms. Immunotherapy is the basic treatment for this disease, including first- and second-line therapies for the acute stage and the long-course therapy for the chronic stage. Anti-NMDAR encephalitis often has a good prognosis, but some patients may still have neurological dysfunction due to poor response to current immunotherapy. In addition, the adverse reactions and economic burden of drugs are practical problems in clinical practice. To solve the above problems, continuous improvements have been made in immunotherapy regimens in terms of dose, route of administration, and course of treatment, and some new immunotherapy drugs have emerged. This article reviews the recent research on immunotherapy for anti-NMDAR encephalitis.
抗 N-甲基-D-天冬氨酸受体（NMDAR）脑炎是一种以神经和精神症状为特征的中枢神经系统疾病。免疫疗法是该病的基本治疗方法，包括急性期的一线和二线治疗以及慢性期的长程治疗。抗 NMDAR 脑炎的预后通常较好，但由于对当前免疫疗法的反应不佳，一些患者仍可能存在神经功能障碍。此外，药物的不良反应和经济负担是临床实践中的实际问题。为了解决上述问题，免疫治疗方案在剂量、给药途径和疗程方面不断得到改进，一些新的免疫治疗药物也相继出现。本文就抗 NMDAR 脑炎的免疫治疗研究进展作一综述。
